Published mark
West Pharmaceutical Services
WEST PHARMACEUTICAL SERVICES INC
NYSE: WST. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:88fa2e30-1e96-4558-bd72-354ffd488578
- SEC CIK
- 0000105770
- Website
- www.westpharma.com Open
- Record version
- vpublic-1:ro-d751713988987e9331980363e24189ce, published Oct 15, 2026
- Newest evidence
- Mar 12, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Eric M. GreenSince Feb 17, 2026
- Chair
- Not published
- Independent
- Not published2 directors published
- Published claims
- 454 distinct sources
- Evidence records
- 240 pinned
- Source conflicts
- 0None open
Built from 4 distinct sources and 24 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Myla P. Lai-Goldman seat on West Pharmaceutical Services, effective 2026-03-12.
EffectiveEffective Mar 12, 2026E9
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Senior Vice President and Chief Human Resources Officer | Annette F. Favorite | Feb 2026 | current | Source reportedE16 |
| Vice President, Finance Chief Accounting Officer | Chad R. Winters | Feb 2026 | current | Source reportedE17 |
| Chair of the Board, President and Chief Executive Officer | Eric M. Green | Feb 2026 | current | Source reportedE18 |
| Senior Vice President, General Counsel and Corporate Secretary | Norman D. Finch Jr. | Feb 2026 | current | Source reportedE19 |
| Senior Vice President Chief Financial Officer | Robert W. McMahon | Feb 2026 | current | Source reportedE20 |
| Senior Vice President, Strategy and Corporate Development | Rudy J. Poussot | Feb 2026 | current | Source reportedE21 |
| Chief Proprietary Segment Officer | Shane A. Campbell | Feb 2026 | current | Source reportedE22 |
Board of directors
Evidence2 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Myla P. Lai-Goldman | Independence not published | 2026 | Audit | Source reportedE9 |
| William F. Feehery | Independence not published | 2026 | Audit | Source reportedE15 |
| David P. Michels | Independence not published | Not published | AuditAudit; Nominating and Corporate GovernanceNominating and Corporate Governance | Source reportedE3 |
| Deborah L. V. Keller | Independence not published | Not published | CompensationCompensation; Nominating and Corporate Governance · ChairNominating and Corporate Governance, chair | Source reportedE4 |
| Dr. Stephen H. Lockhart | Independence not published | Not published | Compensation | Source reportedE23 |
| Eric M. Green | Independence not published | Not published | None published | Source reportedE5 |
| Janet B. Haugen | Independence not published | Not published | Audit, chairAudit · Chair | Source reportedE6 |
| Mark A. Buthman | Independence not published | Not published | Compensation | Source reportedE7 |
| Molly Joseph | Independence not published | Not published | Compensation, chairCompensation · Chair; Nominating and Corporate GovernanceNominating and Corporate Governance | Source reportedE8 |
| Myla P. Lai-Goldman, M.D. | Independence not published | Not published | None published | Source reportedE10 |
| Paolo Pucci | Independence not published | Not published | Audit | Source reportedE11 |
| Robert F. Friel | Independence not published | Not published | Nominating and Corporate Governance | Source reportedE12 |
| Stephen H. Lockhart, M.D., Ph.D. | Independence not published | Not published | None published | Source reportedE13 |
| Wenbin Jiang, Ph.D. | Independence not published | Not published | None published | Source reportedE14 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Janet B. Haugen | Janet B. Haugen, David P. Michels, Myla P. Lai-Goldman, Paolo Pucci, William F. Feehery | Not described in the published record |
| Audit · Chair | Not published | Janet B. Haugen | Not described in the published record |
| Audit; Nominating and Corporate Governance | Not published | David P. Michels | Not described in the published record |
| Compensation | Molly Joseph | Molly Joseph, Deborah L. V. Keller, Dr. Stephen H. Lockhart, Mark A. Buthman | Not described in the published record |
| Compensation · Chair; Nominating and Corporate Governance | Not published | Molly Joseph | Not described in the published record |
| Compensation; Nominating and Corporate Governance · Chair | Not published | Deborah L. V. Keller | Not described in the published record |
| Nominating and Corporate Governance | Deborah L. V. Keller | Deborah L. V. Keller, David P. Michels, Molly Joseph, Robert F. Friel | Not described in the published record |
Committee RecordAudit: Chair Janet B. Haugen; Members Janet B. Haugen (Chair); David P. Michels; Myla P. Lai-Goldman; Paolo Pucci; William F. Feehery
Committee AppointmentJanet B. Haugen: chair, Audit
Committee AppointmentDavid P. Michels: member, Audit
Committee AppointmentMyla P. Lai-Goldman: member, Audit
Committee AppointmentPaolo Pucci: member, Audit
Committee AppointmentWilliam F. Feehery: member, Audit
Committee AppointmentMolly Joseph: chair, Compensation
Committee AppointmentDeborah L. V. Keller: member, Compensation
Committee AppointmentDr. Stephen H. Lockhart: member, Compensation
Committee AppointmentMark A. Buthman: member, Compensation
Committee RecordNominating and Corporate Governance: Chair Deborah L. V. Keller; Members Deborah L. V. Keller (Chair); David P. Michels; Molly Joseph; Robert F. Friel
Committee AppointmentDeborah L. V. Keller: chair, Nominating and Corporate Governance
Committee AppointmentDavid P. Michels: member, Nominating and Corporate Governance
Committee AppointmentMolly Joseph: member, Nominating and Corporate Governance
Committee AppointmentRobert F. Friel: member, Nominating and Corporate Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerEric M. Green, Chair of the Board, President and Chief Executive Officer, from Feb 17, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceIndex MembershipS&P 500 (SPX)
Security ListingWST (NYSE)
Index memberships1 membership attached to a specific security and listing.Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.
SPX
Source reportedAs of Oct 15, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
| Index | Security | Status | Effective | Verification | Source |
|---|---|---|---|---|---|
| S&P 500 (S&P Dow Jones Indices) | NYSE: WST | current | May 22, 2020 | inferred | Slickcharts S&P 500 constituent table (public observation, not S&P DJI license) |
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameWEST PHARMACEUTICAL SERVICES INC
Entity StatusPublic listing published
Official Websitehttps://www.westpharma.com
Published FactUS
Published FactPA
Published FactHealthcare
Published Facthttps://www.westpharma.com
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Annette F. FavoriteSenior Vice President and Chief Human Resources Officercompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:22
- Chad R. WintersVice President, Finance Chief Accounting Officercompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:23
- Eric M. GreenChair of the Board, President and Chief Executive Officer; Directorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:24, company:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:11
- Norman D. Finch Jr.Senior Vice President, General Counsel and Corporate Secretarycompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:25
- Robert W. McMahonSenior Vice President Chief Financial Officercompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:26
- Rudy J. PoussotSenior Vice President, Strategy and Corporate Developmentcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:27
- Shane A. CampbellChief Proprietary Segment Officercompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:28
- Myla P. Lai-GoldmanDirectorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:15
- William F. FeeheryDirectorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:21
- David P. MichelsDirectorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:9
- Deborah L. V. KellerDirectorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:10
- Dr. Stephen H. LockhartDirector (committee appointment)company:88fa2e30-1e96-4558-bd72-354ffd488578:committee_record:35
- Janet B. HaugenDirectorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:12
- Mark A. ButhmanDirectorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:13
- Molly JosephDirectorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:14
- Myla P. Lai-Goldman, M.D.Directorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:16
- Paolo PucciDirectorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:17
- Robert F. FrielDirectorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:18
- Stephen H. Lockhart, M.D., Ph.D.Directorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:19
- Wenbin Jiang, Ph.D.Directorcompany:88fa2e30-1e96-4558-bd72-354ffd488578:leadership_role:20
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 24 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 15, 2026. Cited by 6 Claims.
- E2WEST PHARMACEUTICAL SERVICES INC Form 10-K (filed 2026-02-17). SEC filing. Retrieved Aug 29, 2026. Cited by 2 Claims.
- E3sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E4sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E5sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E6sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E7sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E8sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E9sec filing. Published Mar 12, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E10sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E11sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E12sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E13sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E14sec filing. Published Mar 12, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E15sec filing. Published Mar 12, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E16sec filing. Published Feb 17, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E17sec filing. Published Feb 17, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E18sec filing. Published Feb 17, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E19sec filing. Published Feb 17, 2026. Retrieved May 8, 2026. Cited by 1 Claim.
- E20sec filing. Published Feb 17, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E21sec filing. Published Feb 17, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E22sec filing. Published Feb 17, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E23board_seats. board seats. Cited by 16 Claims.
- E24Slickcharts S&P 500 constituent table (public observation, not S&P DJI license). index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
What changed in version public-1:ro-d751713988987e9331980363e24189ce
vpublic-1:ro-d751713988987e9331980363e24189ce published Oct 15, 2026- Myla P. Lai-Goldman seat on West Pharmaceutical Services, effective 2026-03-12.
- William F. Feehery seat on West Pharmaceutical Services, effective 2026-03-12.
- Annette F. Favorite executive of West Pharmaceutical Services, effective 2026-02-17.
- Chad R. Winters executive of West Pharmaceutical Services, effective 2026-02-17.
- Eric M. Green executive of West Pharmaceutical Services, effective 2026-02-17.
- Norman D. Finch Jr. executive of West Pharmaceutical Services, effective 2026-02-17.
- Robert W. McMahon executive of West Pharmaceutical Services, effective 2026-02-17.
- Rudy J. Poussot executive of West Pharmaceutical Services, effective 2026-02-17.
- Shane A. Campbell executive of West Pharmaceutical Services, effective 2026-02-17.